June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Microbiologic spectrum of post-injection endophthalmitis by indication for intravitreal anti-VEGF therapy
Author Affiliations & Notes
  • Charles Calvo
    Retina Service, Wills Eye Hospital, Philadelphia, PA
  • Nadim Rayess
    Retina Service, Wills Eye Hospital, Philadelphia, PA
  • Ehsan Rahimy
    Retina Service, Wills Eye Hospital, Philadelphia, PA
  • Chirag Shah
    Ophthalmic Consultants of Boston, Boston, MA
  • Jeremy D Wolfe
    Associated Retinal Consultants at William Beaumont Hospital, Royal Oak, MI
  • Eric Chen
    Retina Consultants of Houston, Houston, TX
  • Francis DeCroos
    Southeastern Retina Associates, Chattanooga, TN
  • Sunir J Garg
    Retina Service, Wills Eye Hospital, Philadelphia, PA
  • Jason Hsu
    Retina Service, Wills Eye Hospital, Philadelphia, PA
  • Footnotes
    Commercial Relationships Charles Calvo, None; Nadim Rayess, None; Ehsan Rahimy, None; Chirag Shah, None; Jeremy Wolfe, None; Eric Chen, None; Francis DeCroos, None; Sunir Garg, None; Jason Hsu, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4070. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Charles Calvo, Nadim Rayess, Ehsan Rahimy, Chirag Shah, Jeremy D Wolfe, Eric Chen, Francis DeCroos, Sunir J Garg, Jason Hsu; Microbiologic spectrum of post-injection endophthalmitis by indication for intravitreal anti-VEGF therapy. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4070.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To describe the microbiologic spectrum of endophthalmitis following intravitreal anti-VEGF injections for treatment of neovascular age-related macular degeneration (AMD), diabetic eye disease, and retinal vein occlusion (RVO).

Methods: A multicenter, retrospective, consecutive case series.

Results: Between January 1, 2011 and September 30, 2013, a total of 503,890 intravitreal anti-VEGF injections were performed at the five participating clinical sites. Presumed infectious endophthalmitis occurred in 159 of 416,133 injections performed for neovascular AMD (1/2617), 16 of 40,982 for diabetic eye disease (1/2561), and 8 of 46,775 for RVO (1/5846). For patients with neovascular AMD, 61 of the 159 cases (38%) of endophthalmitis were culture positive, corresponding to a culture positive rate of 1/6822. The cultured organisms included 13 cases of coagulase-negative Staphylococcus, 12 of S. epidermidis, 5 of S. pneumonia, 5 of S. mitis, 5 of methicillin-sensitive S. aureus, 4 of Staphylococcus lugdunesis, 4 of Enterococcus fecalis, 3 of S. viridans, 3 of non-differentiated gram-positive cocci, and 1 case of each of the following organisms: Staphylococcus auricularis, Staphylococcus homininis, Streptococcus sanguis, alpha-hemolytic Streptococcus, Candida parapsicolosis, Propionibacterium, and Lactobacillus. For patients treated for diabetic eye disease, 8 of the 16 cases (50%) were culture positive, providing a culture positive rate of 1/5123. Four eyes grew coagulase-negative Staphylococcus, 2 had S. epidermidis, and there was 1 case of S. pneumonia and 1 case of H. influenzae. For patients with RVO, 4 of the 8 cases (50%) were culture positive, resulting in an overall culture positive rate of 1/11,694. There was 1 case of S. pneumoniae, methicillin-sensitive S. aureus, S. mitis, and coagulase-negative Staphylococcus.

Conclusions: Gram-positive coagulase-negative Staphylococcus was the most common bacteria isolated in cases of post-injection endophthalmitis. A greater proportion of coagulase-negative Staphylococcus was found in endophthalmitis following injections for diabetic eye disease (75%) compared to AMD (51%) and RVO (25%). Oral flora pathogens accounted for 22% of the cases.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.